Rocket Pharmaceuticals, INC 10-Q quarterly reports

Rocket Pharmaceuticals reports a significant financial boost from a $180 million Priority Review Voucher sale and FDA accelerated approval for its KRESLADI gene therapy, while advancing its cardiovascular pipeline.

Rocket Pharmaceuticals reports a reduced net loss in Q3 2025, driven by strategic restructuring and pipeline prioritization, despite clinical setbacks for RP-A501 and ongoing legal challenges.

Rocket Pharmaceuticals announced a strategic reorganization to prioritize its AAV-based cardiovascular gene therapy platform, reducing its workforce by 30% and extending its cash runway into Q2 2027, despite a clinical hold on its Danon disease trial.

Rocket Pharmaceuticals reports a net loss of $61.33 million for Q1 2025, with R&D expenses decreasing and G&A expenses increasing, while advancing its gene therapy programs.

Rocket Pharmaceuticals reported its Q3 2024 financial results and provided updates on its gene therapy programs, including a CRL for its LAD-I BLA and progress in other clinical trials.

Rocket Pharmaceuticals reported its second quarter 2024 financial results and provided updates on its clinical programs, including a Complete Response Letter from the FDA for its LAD-I program.

Rocket Pharmaceuticals reported its first quarter 2024 financial results, highlighting progress in its gene therapy programs and regulatory milestones.